ClinicalTrials.gg
Active, not recruitingNCT06455787JOURNEYUpdated Oct 29, 2026

J-Valve Transfemoral Pivotal Study

An interventional study of J-Valve Transfemoral (TF) System in Aortic Valve Regurgitation and Aortic Valve Disease Mixed, sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences LLC. Active, not recruiting at 42 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by JC Medical, Inc., an affiliate of Edwards Lifesciences LLC (part of Edwards Lifesciences) · Not applicable, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now Active, not recruiting2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
194
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences — 1 open to participants now, 4 under way, none of them phase 3. Aortic Valve Insufficiency · Edwards Lifesciences.

Planned enrollment
5th of 10
194 · median 164
Started
2024
the only one that year
No phase
10 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences, this one is the 5th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 10 with no phase, and was the 10th registered.

Aortic Valve Insufficiency

171 studies on the registry are indexed under Aortic Valve Insufficiency; 56 are open to participants now.

Browse Aortic Valve Insufficiency studies →

Open to participants now

1 of the 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 39 Aortic Valve Insufficiency studies recruiting now, 31 (79%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Aortic Valve Insufficiency by Edwards Lifesciences, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR).

A Cardiac Magnetic Resonance (CMR) sub-study will examine if intervention for AR translates to improved ventricular remodeling, the impact of LV remodeling on clinical outcomes and quality of life, as well as volumetric and myocardial differences between genders.

Read the detailed description

This is a prospective, single arm, multi-center, interventional pivotal study that will enroll up to 194 subjects in up to 35 investigational sites, predominantly in the United States and up to 7 in Canada, Europe, and Japan. Of the 194 subjects, the CMR imaging sub-study will include up to 75 subjects with severe AR already confirmed by TTE. Additionally, up to 40 roll-in subjects may be treated to enable clinical experience and exposure to the device while allowing a reasonable learning curve. The subjects will then be followed 5-years post-procedure of the J-Valve TF System.

03

Conditions studied

  • Aortic Valve Regurgitation
  • Aortic Valve Disease Mixed

Keywords

  • J-Valve Transfemoral System
  • Transcatheter Therapy
  • Transcatheter Aortic Valve Replacement
  • TAVR
  • Transfemoral
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Symptomatic according to (NYHA) functional class (FC) II or higher
  2. Severe AR, defined as follows, as assessed by Imaging Core Laboratory:

    A. Severe AR by Transthoracic Echocardiography (TTE) (grade 3 or 4)

    B. OR, if indeterminate AR, by TTE, ANY ONE of the following:

    i. Cardiac magnetic resonance imaging (CMR)-derived aortic regurgitant fraction (RF) ≥43% ii. CMR-derived RF ≥33% + left ventricular dilation (left ventricular end diastolic volume index [LVEDVi]) >105 mL/m\^2 for men or LVEDVi >96 mL/m\^2 for women) iii. CMR-derived RF ≥33% + LV (LVEF) ≤55% or left ventricular end systolic volume index (LVESVi) ≥43mL/m\^2; iv. Severe AR by Transesophageal Echocardiography (TEE) (grade 3 or 4)

  3. High risk for surgery as judged by a multi-disciplinary heart team
  4. Suitable anatomy to accommodate the insertion, delivery, and deployment of the study devices (see anatomic exclusions below)
  5. Written and agreement to comply with all required post-procedure follow-up visits at site.

Exclusion criteria

Exclusion Criteria:

  1. Previous prosthetic aortic valve (bioprosthesis or mechanical) implant
  2. Aortic valve stenosis > moderate*
  3. Severe mitral valve or tricuspid valve regurgitation*
  4. Severe mitral valve or tricuspid valve stenosis*
  5. Active infection, including infective endocarditis
  6. Cardiac imaging evidence of cardiac mass, thrombus or vegetation
  7. Inability to tolerate or a condition precluding treatment with antithrombotic (antiplatelet, anticoagulant) therapy
  8. Renal insufficiency ( \<30 mL/min/1.73m\^2) or end stage renal disease requiring chronic dialysis
  9. Liver disease (cirrhosis of the liver [ Class B or C])
  10. Blood dyscrasias as defined: leukopenia (WBC \<3000 cells/mcL), thrombocytopenia ( count \<50,000 cells/mcL), anemia ( \<9 g/dL), history of bleeding diathesis coagulopathy, or hypercoagulable state (unless therapeutically stable)
  11. Known or to aspirin, heparin, bivalirudin, clopidogrel, Nitinol (Nickel, Titanium) or sensitivity to contrast media, which cannot be adequately premedicated
  12. Left ventricular dysfunction with (LVEF) \<25% as measured by resting echocardiogram (or by CMR, when performed)*
  13. untreated coronary artery disease requiring revascularization or anticipated coronary revascularization procedure within 12-months post index procedure
  14. Acute myocardial infarction within 30 days prior to index procedure
  15. PCI within 30 days prior to index procedure
  16. Carotid intervention within 6 weeks prior to index procedure or carotid artery disease requiring intervention
  17. Previous, or planned, other surgical or interventional procedures within 30 days before, during, or within 30 days after the index procedure
  18. Uncontrolled atrial fibrillation
  19. Severe right ventricular (RV) dysfunction*
  20. Pulmonary hypertension (systolic PA pressure >70mmHg or systolic PA pressure ≥2/3 of systemic systolic BP)
  21. Severe (COPD) requiring chronic oral or requiring continuous home O2
  22. Stroke (CVA), (TIA) or neurological signs and symptoms attributed to carotid or vertebrobasilar disease within 90 days prior to index procedure
  23. Cardiogenic shock defined as systolic blood pressure \<90 mmHg in addition to signs of tissue hypoperfusion or the need for vasopressors and/or mechanical hemodynamic support to maintain systolic blood pressure ≥90mmHg
  24. Patient requires mechanical circulatory support within 30 days prior to index procedure
  25. Estimated of less than 24 months due to associated non-cardiac co-morbid conditions
  26. Pregnancy or intent to become pregnant prior to completion of all protocol follow-up requirements
  27. Participation in another study that has not reached its primary endpoint
  28. Considered to be part of a vulnerable population

    • As assessed by Imaging Core Laboratory

Anatomic Exclusions:

  1. Ascending Aortic diameter >5 cm*
  2. Aortic Annulus Perimeter \<57 mm or >104 mm*
  3. Inappropriate anatomy for femoral introduction and delivery of the study system
  4. Left ventricular end-diastolic diameter (LVEDD) >75 mm*
  5. Congenital aortic valve disease including Unicuspid, Bicuspid, or Quadricuspid aortic valve anatomy*
  6. Congenital univentricle or other condition that, in the opinion of the investigator and/or consulting physician, may constitute an unwarranted surgical risk
  7. Excessive aortic valve prolapse that would preclude proper seating of the implant in the aortic annulus
  8. Abdominal/thoracic aortic aneurysm ≥5.0 cm*
  9. Aorto-iliac disease requiring intervention to facilitate delivery of access sheath
  10. Excessive tortuosity of delivery system pathway, defined as severe tortuosity of multiple vessels including iliofemoral, thoracoabdominal aorta, aortic arch, or LV-aortic root angle >80⁰
  11. Non-native anatomy in aortic zones 0A \& 0B (aortic valve annulus to the distal margin of the right pulmonary artery); 0C (to innominate) only if deemed unfavorable by the Study Screening Committee

    • As assessed by Imaging Core Laboratory
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
194 participants (estimated)

Study arms

  • Experimental
    J-Valve Transfemoral (TF) System

    Device: J-Valve Transfemoral (TF) System

Interventions

  • DeviceJ-Valve Transfemoral (TF) System

    Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR). The Edwards 16Fr eSheath+ Introducer Set may be used for the introduction and removal of the J-Valve TF System.

06

What researchers measure

Primary outcomes

  1. All-cause mortality at 1 year

    Time frame: 1-year post-procedure

  2. The composite rate of early-safety outcomes at 30 days as defined by the Valve Academic Research Consortium 3 (VARC-3)

    Includes: * All-cause death * All stroke * VARC-3 type 2-4 bleeding * Major vascular, access-related, or cardiac structural complication * Acute kidney injury (AKI) stage 3 or 4 * New permanent pacemaker due to procedure-related conduction abnormalities * Surgery or intervention related to the device

    Time frame: 30-days post-procedure

Secondary outcomes

  1. Rate of improvement in cardiovascular-specific health status

    As measured by the Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OS)

    Time frame: Baseline to 1-year follow-up

  2. Improvement in left ventricular end diastolic diameter index (LVEDDi)

    To measure LV remodeling

    Time frame: Baseline to 1-year follow-up

  3. Improvement in left ventricular end diastolic volume index (LVEDVi)

    To measure LV remodeling

    Time frame: Baseline to 1-year follow-up

  4. Improvement in effective stroke volume index (ESVi)

    To measure LV remodeling

    Time frame: Baseline to 1-year follow-up

  5. Improvement in effective cardiac output index (ECOi)

    To measure LV remodeling

    Time frame: Baseline to 1-year follow-up

07

Study locations

42 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Feb 2028, 40 months after the start.

Of 44 interventional studies with no phase under Aortic Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 74. This study's planned 40 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2024
First posted
Jun 12, 2024
StartActual
Oct 17, 2024
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2032
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 29, 2026
Sites
2 sites added
Show 2 added (1 United States, 1 Japan)
  • Banner University Medical Center - Phoenix · Phoenix, United States
  • National Cerebral and Cardiovascular Center · Osaka, Japan
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Active, not recruiting
    2 sites added
    Show 2 added (1 United States, 1 Japan)
    • Banner University Medical Center - Phoenix · Phoenix, United States
    • National Cerebral and Cardiovascular Center · Osaka, Japan
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06455787
Collaborators
Minneapolis Heart Institute Foundation, Cardiovascular Research Foundation, New York
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Oct 17, 2024
Primary completion
Feb 2028 (estimated)
Completion
Feb 2032 (estimated)
Last update
Oct 29, 2026

Study contacts

Dean J Kereiakes, MD
study chair · The Christ Hospital Heart & Vascular Institute
Michael Reardon, MD
study chair · The Methodist Hospital Research Institute
Santiago Garcia, MD
principal investigator · The Christ Hospital and The Carl and Edyth Lindner Center for Research and Education
Tsuyoshi Kaneko, MD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion